ipilimumab,nivolumab
bms
['nivo', 'scandium', 'scandium2']
also at #asco23 the phase i #scandium2 trial exploring the combination of #ihp and ipi3/nivo1 in 18 patients will be presented. there was a high yet manageable toxicity profile, but with encouraging efficacy, 18% cr and 24% pr! 
Professor in Cancer Surgery at Sahlgrenska University Hospital. @sahlgrenska @SahlgrenskaAcad @goteborgUni #wcmtm #melanoma #breastcancer #surgery